ABX464 + Placebo
Phase 2/3Terminated 0 watching 0 views this week📈 Rising
62
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
COVID-19
Conditions
COVID-19
Trial Timeline
Jul 1, 2020 → Apr 16, 2021
NCT ID
NCT04393038About ABX464 + Placebo
ABX464 + Placebo is a phase 2/3 stage product being developed by Abivax for COVID-19. The current trial status is terminated. This product is registered under clinical trial identifier NCT04393038. Target conditions include COVID-19.
Hype Score Breakdown
Clinical
22
Activity
15
Company
7
Novelty
7
Community
8
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05535946 | Phase 3 | Active |
| NCT05507216 | Phase 3 | Completed |
| NCT05507203 | Phase 3 | Completed |
| NCT03905109 | Phase 2/3 | Withdrawn |
| NCT05032560 | Phase 1 | Completed |
| NCT04393038 | Phase 2/3 | Terminated |
| NCT02735863 | Phase 2 | Completed |
Competing Products
20 competing products in COVID-19
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Human COVID-19 immunoglobulin (pH4) for intravenous injection + Placebo | Sinopharm | Phase 2 | 51 |
| Mavrilimumab + Placebos | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Gimsilumab + Placebo | Roivant Sciences | Phase 2 | 49 |
| Icosapent ethyl | Amarin Corporation | Phase 2 | 44 |
| Bamlanivimab + Placebo + Etesevimab | Eli Lilly | Phase 3 | 77 |
| Infliximab | Celltrion | Phase 2 | 52 |
| CT-P63 and CT-P66 / Placebo | Celltrion | Phase 3 | 77 |
| Enzalutamide Pill | Astellas Pharma | Phase 2 | 52 |
| S-892216 + Placebo | Shionogi | Phase 2 | 52 |
| S-892216 + Carbamazepine | Shionogi | Phase 1 | 33 |
| FOY-305 + Placebo | Ono Pharmaceutical | Phase 3 | 77 |
| Desidustat | Zydus Lifesciences | Phase 2 | 52 |
| LY3819253 + Placebo | Eli Lilly | Phase 1 | 33 |
| Bamlanivimab + Etesevimab + Placebo + VIR-7831 + Bebtelovimab | Eli Lilly | Phase 2 | 52 |
| Bamlanivimab | Eli Lilly | Phase 2 | 52 |
| LY3127804 + Placebo | Eli Lilly | Phase 2 | 52 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Bamlanivimab | Eli Lilly | Pre-clinical | 23 |
| LY3819253 + Placebo + Remdesivir | Eli Lilly | Phase 3 | 77 |
| LY3819253 + LY3832479 + LY3853113 + Placebo | Eli Lilly | Phase 2/3 | 65 |